Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Stanton, Sasha E ^a,b   Ward, Maureen M ^a   Christos, Paul ^a   Sanford, Rachel ^a   Lam, Christina ^a   Cobham, Marta V ^a   Donovan, Diana ^a   Scheff, Ronald J ^a   Cigler, Tessa ^a   Moore, Anne ^a   Vahdat, Linda T ^a   Lane, Maureen E ^a   Chuang, Ellen ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Breast cancer; Her2 neu; Pro 1170 Ala polymorphism; Single nucleotide polymorphisms; Trastuzumab cardiotoxicity

Indexed keywords

ADENINE; ALANINE; CYTOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; GUANINE; ISOLEUCINE; PROLINE; TRASTUZUMAB; VALINE; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CODON; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG WITHDRAWAL; ERBB2 GENE; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MEDICAL HISTORY; PREDICTION; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST NEOPLASMS; CHEMICALLY INDUCED; GENETIC ASSOCIATION STUDY; GENETICS; HEART DISEASE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARDIOTOXICITY; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEART DISEASES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS; TRASTUZUMAB;

EID: 84928153435     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1298-6     Document Type: Article

References (18)

1. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007;81(3):328-45.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
3. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820-6.
4. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-21.
5. Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2011;37(4):312-20.
6. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459-65.
7. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99(13):8880-5.
8. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378(6555):394-8.
9. Zambelli A, Della Porta MG, Eleuteri E, De Giuli L, Catalano O, Tondini C, et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast. 2011;20(2):176-83.
10. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25(23):3525-33.
11. Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, McCredie MR, et al. The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1109-11.
12. Rutter JL, Chatterjee N, Wacholder S, Struewing J. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology. 2003;14(6):694-700.
13. Han X, Diao L, Xu Y, Xue W, Ouyang T, Li J, et al. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. Ann Oncol. 2014;25(6):1158-64.
14. Han W, Kang D, Lee JE, Park IA, Choi JY, Lee KM, et al. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res. 2005;11(13):4775-8.
15. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2000;92(5):412-7.
16. Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol. 2007;18(8):1335-41.
17. Lu S, Wang Z, Liu H, Hao X. HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies. Breast Cancer Res Treat. 2010;124(3):771-8.
18. Wang V, Chuang TC, Kao MC, Shan DE, Soong BW, Shieh TM. Polymorphic Ala-allele carriers at residue 1170 of HER2 associated with Parkinson's disease. J Neurol Sci. 2013;325(1-2):115-9.